Skip to content

Immunovant, Inc. IMVT Cash Flow Statement

Q4 '26Q3 '26Q2 '26Q1 '26Q4 '25
-$147.86M-33.6%-$110.64M+12.5%-$126.5M-4.9%-$120.61M-13.3%-$106.45M+4.2%
$96K-5.0%$101K-3.8%$105K-1.9%$107K-1.8%$109K+10.1%
$11.14M-12.4%$12.72M-4.8%$13.36M-27.8%$18.51M+58.4%$11.69M+0.3%
-$95.06M-3.0%-$92.33M+9.9%-$102.52M+12.7%-$117.41M-6.1%-$110.64M-10.2%
$8K$0$0$0-100%$201K+11.7%
-$8K$0$0$0+100%-$201K-11.7%
$3.64M-99.4%$564.6M+2,196%$24.6M+743%$2.92M-99.4%$450.61M+18,188%
$472.66M+714%-$77.04M+33.0%-$115.06M-134%$339.29M+445%
-$95.07M-3.0%-$92.33M+9.9%-$102.52M+12.7%-$117.41M-5.9%-$110.84M-10.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Immunovant, Inc. generate?
Immunovant, Inc. (IMVT) generated -$407.3M in operating cash flow over the trailing twelve months.
What is Immunovant, Inc.'s free cash flow?
After $8.0K of capital expenditures, Immunovant, Inc.'s free cash flow was -$407.3M over the trailing twelve months, down 8.2% year over year.
Where does Immunovant, Inc.'s cash flow data come from?
Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.